It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes
- Rémi J. Creusot1,
- Nick Giannoukakis2,
- Massimo Trucco2,
- Michael J. Clare-Salzler3 and
- C. Garrison Fathman4⇑
- 1Department of Medicine, Columbia Center for Translational Immunology and Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, NY
- 2Division of Immunogenetics, Department of Pediatrics, John G. Rangos Research Center, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 3Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL
- 4Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
- Corresponding author: C. Garrison Fathman, .
Jump to section
- Natural Tolerogenic APCs
- Why Use DCs as Therapeutic Tolerogenic Cells?
- Is DC Therapy Effective and Safe?
- Producing and Manipulating Clinical-Grade DCs
- Targeting the Relevant T Cells: Is Antigen Provision to the Tolerogenic DC Required?
- Dealing With Two Facets of DC Maturity
- Targeting Relevant Tissues With DCs
- Deciding on the Time of Intervention, Dose, and Number of Injections
- Enhancing the Tolerogenic Function of DCs With Combination Therapies
- Article Information
- Figures & Data
- Info & Metrics